Boehringer Ingelheim Buys ADC Specialist NBE-Therapeutics for US$1.43 B
By Ashish Tripathi & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)
Published: 5 Feb-2021
DOI: 10.3833/pdr.v2021.i2.2590 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Reinforcing its commitment to oncology, Boehringer Ingelheim has agreed to acquire NBE-Therapeutics in a deal worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018